Compare AYTU & HERZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AYTU | HERZ |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 32.3M |
| IPO Year | 2015 | N/A |
| Metric | AYTU | HERZ |
|---|---|---|
| Price | $2.16 | $17.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.33 | N/A |
| AVG Volume (30 Days) | ★ 23.4K | 21.8K |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,632,080.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $43.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 277.47 | N/A |
| 52 Week Low | $1.65 | $1.62 |
| 52 Week High | $3.07 | $19.30 |
| Indicator | AYTU | HERZ |
|---|---|---|
| Relative Strength Index (RSI) | 45.37 | 47.51 |
| Support Level | $2.08 | $15.95 |
| Resistance Level | $2.32 | $17.42 |
| Average True Range (ATR) | 0.09 | 0.61 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 33.39 | 56.72 |
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
Herzfeld Credit Income Fund Inc is a non-diversified, closed-end management investment company. Its primary investment objective is to maximize risk-adjusted total returns, and its secondary investment objective is to generate high current income.